SOLID TUMOR

This early-stage study tested a new oral medication called CUDC-907 in children and young adults whose cancers had returned or stopped responding to standard treatments. The main goals were to check for side effects and find the safest dose for children, since this drug had only …

This study tested a new combination drug (MK-4280A) to see if it could help people with certain advanced cancers. It involved 163 people with either a type of advanced skin cancer (cSCC) or a type of endometrial cancer that had spread or returned. The goal was to see if the drug …

This early-stage study tested a new oral drug called ZN-c3 in adults with advanced solid tumors that had stopped responding to standard treatments. Researchers aimed to find the safest dose and see if the drug shows any signs of fighting cancer. The trial also checked whether tak…

This early-stage study tested a new cancer drug called RC108-ADC in 67 patients with advanced solid tumors that had a specific marker (c-Met positive). The main goals were to find the highest safe dose and check for side effects. Researchers also measured how the drug moved throu…

This small, early-stage study tested a new cell therapy called QH104 for patients with advanced solid tumors that had spread to the lining of the brain (meninges). The therapy involved injecting specially engineered immune cells directly into the spinal fluid to try to attack the…

This early-stage study aimed to find safe doses for several different combinations of cancer drugs in patients with advanced or metastatic solid tumors, including lung cancer. The 60 participants were divided into groups to test combinations of chemotherapy, immunotherapy, and ta…

This study tested whether a smartphone app could help cancer patients remember to take their oral medications better than a traditional paper diary. It involved 124 adults with various cancers who were prescribed pill-based treatments. Researchers compared the two methods to see …

This early-stage study aimed to find a safe dose and understand how the body processes a new experimental drug called boserolimab. It involved 182 adults with advanced cancers, including lung and breast cancer, who had run out of standard treatment options. Researchers tested bos…

This study tested a new three-drug combination (afuresertib, sintilimab, and chemotherapy) for people with advanced solid tumors that had stopped responding to prior immunotherapy. The goal was to find a safe, effective dose and see if this combination could help control cancer g…

This early-stage trial tested a new drug called ALRN-6924, alone or with another cancer drug, in 142 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug could shrink tumors …

This early-stage study tested a new drug called JAB-BX102, both alone and combined with an existing immunotherapy (pembrolizumab), in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find safe dose levels and see if t…

This study tested whether combining two, three, or four different immunotherapy drugs could help control advanced prostate cancer that had stopped responding to standard hormone therapy. The trial enrolled 59 adults with this type of cancer or other advanced solid tumors. Researc…

This study tested whether a precise form of radiation therapy using proton beams could stop the growth of tumors that spread to the liver from other cancers. 92 participants with 1-4 liver tumors received 2-3 radiation treatments per week for two weeks. The goal was to control th…

This study tested the safety and initial effectiveness of a combination of two immunotherapy drugs, nivolumab and ipilimumab, in Chinese patients with advanced solid tumors that had returned or spread after prior treatment. The main goals were to see what side effects occurred an…

This small pilot study tested whether doctors could safely adjust proton radiation treatment plans in real-time while a patient is on the treatment table. The goal was to see if this daily adaptation method is practical and safe for treating solid tumors, aiming to better target …

This early-stage study tested a new injectable drug called HCW9218 in 18 people with advanced solid tumors that had stopped responding to at least two prior treatments. The main goal was to find the highest safe dose. The drug is designed to work like a double agent: it aims to b…

This early-stage trial tested the safety of a new experimental treatment called TILT-123, a genetically modified virus designed to infect and kill cancer cells. The virus was injected directly into tumors in 32 patients with advanced solid cancers that had stopped responding to s…

This study tested a new drug called RC88 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug showed early signs of helping to shrink tumors. The trial involved 198 participants with s…

This early-stage study tested a new drug called FS1502 in people with advanced cancers that have a specific marker called HER2. The trial first checked if different doses were safe for various solid tumors, then focused on patients with advanced HER2-positive breast cancer who ha…

This first-in-human study tested a new oral medication called LP-118 in patients with advanced cancers that had stopped responding to other treatments. The main goals were to find a safe dose, see how the body processes the drug, and check for early signs that it might help contr…

This was the first-ever study in people to test the safety and early effects of two new cancer drugs, BNT152 and BNT153, developed by BioNTech. It involved 86 adults with advanced solid tumors that had spread or could not be removed by surgery, and for whom standard treatments we…

This early-stage study aimed to find a safe and effective dose of a new drug called TPST-1495, given alone or with an existing immunotherapy (pembrolizumab), for people with advanced solid tumors. It enrolled 89 adults with cancers like colorectal, lung, and head and neck cancer …

This first-in-human study tested a new drug called SAIL66 in 22 patients with advanced solid tumors that have a specific marker called CLDN6. The main goals were to find a safe dose and see how the body processes the drug, while also checking for any early signs that it might hel…

This early-stage study tested a new cancer drug called IBI129 in people with advanced solid tumors that cannot be removed by surgery. The main goals were to find a safe and effective dose and to see how the body processes the drug. About 180 adults with various types of advanced …

This early-stage trial tested a new oral medication called Q702 in patients with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and understand how the drug moves through the body. Researchers enrolled 51 adults …

This early-stage study aimed to understand how the body processes a single dose of an experimental cancer drug called IMP4297. Six healthy adult male volunteers took the drug so researchers could track how it was absorbed, broken down, and eliminated. The goal was to gather basic…

This study aimed to understand how often a muscle enzyme called CPK increases in cancer patients taking a common type of drug called tyrosine kinase inhibitors (TKIs). It involved 154 patients with solid tumors who had been on TKI treatment for at least a week. The researchers ch…

This was a first-in-human study to test a new radioactive imaging agent called 68Ga-NOTA-SNA002. It involved 17 adult patients with various solid tumors to see if the agent was safe and to measure how much radiation the body absorbs from it. The main goal was to understand how th…

This study aimed to see if two different capsule strengths (10 mg and 20 mg) of an experimental cancer drug called IMP4297 are absorbed by the body in the same way. It involved 28 healthy Chinese male volunteers who each took the drug in two different forms. The main goal was to …

This study aimed to see if two different capsule strengths of a potential cancer drug, IMP4297, are absorbed by the body in the same way. It involved 36 healthy Chinese male volunteers who took the drug after a meal. The main goal was to gather data on how the drug moves through …